Literature DB >> 20615977

Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.

Ayse Ulusoy1, Gurdal Sahin, Deniz Kirik.   

Abstract

Drug-induced dyskinesias in dopamine-denervated animals are known to depend on both pre- and postsynaptic changes of the nigrostriatal circuitry. In lesion models used thus far, changes occur in both of these compartments and, therefore, it has not been possible to dissect the individual contribution of each compartment in the pathophysiology of dyskinesias. Here we silenced the nigrostriatal dopamine neurotransmission without affecting the anatomical integrity of the presynaptic terminals using a short-hairpin RNA-mediated knockdown of tyrosine hydroxylase enzyme (shTH). This treatment resulted in significant reduction (by about 70%) in extracellular dopamine concentration in the striatum as measured by on-line microdialysis. Under these conditions, the animals remained nondyskinetic after chronic L-DOPA treatment, whereas partial intrastriatal 6-hydoxydopamine lesioned rats with comparable reduction in extracellular dopamine levels developed dyskinesias. On the other hand, apomorphine caused moderate to severe dyskinesias in both groups. Importantly, single-dose L-DOPA challenge in apomorphine-primed shTH animals failed to activate the already established abnormal postsynaptic responses. Taken together, these data provide direct evidence that the status of the presynaptic, DA releasing compartment is a critical determinant of both the induction and maintenance of L-DOPA-induced dyskinesias.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20615977      PMCID: PMC2919904          DOI: 10.1073/pnas.1003432107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Local gene knockdown in the brain using viral-mediated RNA interference.

Authors:  Jonathan D Hommel; Robert M Sears; Dan Georgescu; Diana L Simmons; Ralph J DiLeone
Journal:  Nat Med       Date:  2003-11-23       Impact factor: 53.440

2.  PET studies and physiopathology of motor fluctuations in Parkinson's disease.

Authors:  G Linazasoro; K L Leenders
Journal:  Brain       Date:  2004-08       Impact factor: 13.501

3.  Spontaneous synaptic potentials in dopamine-denervated neostriatal neurons.

Authors:  E Galarraga; J Bargas; D Martínez-Fong; J Aceves
Journal:  Neurosci Lett       Date:  1987-10-29       Impact factor: 3.046

4.  Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease.

Authors:  C J Pycock; C D Marsden
Journal:  J Neurol Sci       Date:  1977 Jan-Feb       Impact factor: 3.181

5.  Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.

Authors:  U K Rinne; A Laihinen; J O Rinne; K Någren; J Bergman; U Ruotsalainen
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

6.  L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

Authors:  Christian Winkler; Deniz Kirik; Anders Björklund; M Angela Cenci
Journal:  Neurobiol Dis       Date:  2002-07       Impact factor: 5.996

7.  [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.

Authors:  A Antonini; J Schwarz; W H Oertel; H F Beer; U D Madeja; K L Leenders
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

8.  Regulation of dopamine levels in intrastriatal grafts of fetal mesencephalic cell suspension: an in vivo voltammetric approach.

Authors:  H Moukhles; C Forni; A Nieoullon; A Daszuta
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

9.  Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study.

Authors:  Gurutz Linazasoro; Nadege Van Blercom; Alberto Bergaretxe; Fernández Manchola Iñaki; Enrique Laborda; José Angel Ruiz Ortega
Journal:  Clin Neuropharmacol       Date:  2009 Nov-Dec       Impact factor: 1.592

10.  Dopa-responsive dystonia: long-term treatment response and prognosis.

Authors:  T G Nygaard; C D Marsden; S Fahn
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

View more
  20 in total

Review 1.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 2.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 3.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

Review 4.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

5.  Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats.

Authors:  Javad Mahmoudi; Alireza Mohajjel Nayebi; Siyamak Reyhani-Rad; Morteza Samini
Journal:  Adv Pharm Bull       Date:  2012-06-15

6.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.

Authors:  Kathy Steece-Collier; David J Rademacher; Katherine Soderstrom
Journal:  Basal Ganglia       Date:  2012-02-11

7.  Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study.

Authors:  Merlene Miller; Amanda L C Chen; Stan D Stokes; Susan Silverman; Abdalla Bowirrat; Matthew Manka; Debra Manka; David K Miller; Kenneth Perrine; Thomas J H Chen; John A Bailey; William Downs; Roger L Waite; Margaret A Madigan; Eric R Braverman; Uma Damle; Mallory Kerner; John Giordano; Siobhan Morse; Marlene Oscar-Berman; Debmalya Barh; Kenneth Blum
Journal:  J Psychoactive Drugs       Date:  2012 Nov-Dec

Review 8.  Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.

Authors:  Elisabetta Tronci; Veronica Francardo
Journal:  J Neural Transm (Vienna)       Date:  2017-12-14       Impact factor: 3.575

9.  A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.

Authors:  N Brehm; F Bez; T Carlsson; B Kern; S Gispert; G Auburger; M A Cenci
Journal:  Mol Neurobiol       Date:  2014-10-12       Impact factor: 5.590

10.  Striatal Neurotransmitter Release-related Presynaptic Proteins in L-dopa Induced Dyskinesia in a Model of Parkinsonism.

Authors:  Gül Yalçin Çakmakli; Atay Vural; Emine Eren Koçak; Bülent Elibol; Esen Saka
Journal:  Noro Psikiyatr Ars       Date:  2018-03-19       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.